JP2019523241A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523241A5 JP2019523241A5 JP2018568837A JP2018568837A JP2019523241A5 JP 2019523241 A5 JP2019523241 A5 JP 2019523241A5 JP 2018568837 A JP2018568837 A JP 2018568837A JP 2018568837 A JP2018568837 A JP 2018568837A JP 2019523241 A5 JP2019523241 A5 JP 2019523241A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- och
- fluoroalkyl
- hydroxyalkyl
- cyanoalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 57
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 56
- -1 2 - cyclopropyl Chemical group 0.000 claims 56
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 31
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 22
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000003386 piperidinyl group Chemical group 0.000 claims 16
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 15
- 125000002757 morpholinyl group Chemical group 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 125000003566 oxetanyl group Chemical group 0.000 claims 11
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000002393 azetidinyl group Chemical group 0.000 claims 9
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 9
- 125000002883 imidazolyl group Chemical group 0.000 claims 8
- 125000004193 piperazinyl group Chemical group 0.000 claims 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims 8
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 8
- 125000000335 thiazolyl group Chemical group 0.000 claims 8
- 125000001425 triazolyl group Chemical group 0.000 claims 8
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims 5
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000004965 chloroalkyl group Chemical group 0.000 claims 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- 150000004867 thiadiazoles Chemical class 0.000 claims 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000003725 azepanyl group Chemical group 0.000 claims 2
- 125000004799 bromophenyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000005959 diazepanyl group Chemical group 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611022328 | 2016-06-29 | ||
| IN201611022328 | 2016-06-29 | ||
| US15/635,055 US10071079B2 (en) | 2016-06-29 | 2017-06-27 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| US15/635,055 | 2017-06-27 | ||
| PCT/US2017/039633 WO2018005586A1 (en) | 2016-06-29 | 2017-06-28 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2019523241A JP2019523241A (ja) | 2019-08-22 |
| JP2019523241A5 true JP2019523241A5 (https=) | 2020-08-06 |
| JP6995067B2 JP6995067B2 (ja) | 2022-01-14 |
| JP6995067B6 JP6995067B6 (ja) | 2023-12-14 |
Family
ID=60805851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568837A Active JP6995067B6 (ja) | 2016-06-29 | 2017-06-28 | ［１，２，４］トリアゾロ［１，５－ａ］ピリジニル置換インドール化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (8) | US10071079B2 (https=) |
| EP (1) | EP3478682B1 (https=) |
| JP (1) | JP6995067B6 (https=) |
| KR (1) | KR102473482B1 (https=) |
| CN (1) | CN109641895B (https=) |
| AR (1) | AR108905A1 (https=) |
| AU (1) | AU2017287902B2 (https=) |
| CL (1) | CL2018003821A1 (https=) |
| CO (1) | CO2019000686A2 (https=) |
| CY (1) | CY1124514T1 (https=) |
| DK (1) | DK3478682T3 (https=) |
| EA (1) | EA037530B1 (https=) |
| ES (1) | ES2886964T3 (https=) |
| HR (1) | HRP20211261T8 (https=) |
| HU (1) | HUE056091T2 (https=) |
| IL (1) | IL263961B (https=) |
| LT (1) | LT3478682T (https=) |
| MX (1) | MX376212B (https=) |
| MY (1) | MY196474A (https=) |
| PE (1) | PE20190324A1 (https=) |
| PL (1) | PL3478682T3 (https=) |
| PT (1) | PT3478682T (https=) |
| RS (1) | RS62292B1 (https=) |
| SG (1) | SG11201811590RA (https=) |
| SI (1) | SI3478682T1 (https=) |
| SM (1) | SMT202100513T1 (https=) |
| TW (1) | TWI636053B (https=) |
| UY (1) | UY37310A (https=) |
| WO (1) | WO2018005586A1 (https=) |
| ZA (1) | ZA201900571B (https=) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| BR112019001270A2 (pt) | 2016-07-30 | 2019-04-30 | Bristol-Myers Squibb Company | compostos indol substituídos com dimetoxifenila como inibidores de tlr7, tlr8 ou tlr9 |
| JP7028861B2 (ja) | 2016-09-09 | 2022-03-02 | ブリストル－マイヤーズ スクイブ カンパニー | ピリジル置換のインドール化合物 |
| IL265921B2 (en) | 2016-10-14 | 2024-05-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| WO2019028302A1 (en) | 2017-08-04 | 2019-02-07 | Bristol-Myers Squibb Company | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS |
| KR102688509B1 (ko) | 2017-08-04 | 2024-07-24 | 브리스톨-마이어스 스큅 컴퍼니 | [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물 |
| JP7265554B2 (ja) | 2017-11-14 | 2023-04-26 | ブリストル－マイヤーズ スクイブ カンパニー | 置換インドール化合物 |
| KR102781141B1 (ko) * | 2017-12-15 | 2025-03-13 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 인돌 에테르 화합물 |
| JP7304352B2 (ja) | 2017-12-19 | 2023-07-06 | ブリストル－マイヤーズ スクイブ カンパニー | ６－アザインドール化合物 |
| WO2019126081A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Amide substituted indole compounds useful as tlr inhibitors |
| MX2020005462A (es) * | 2017-12-19 | 2020-09-07 | Bristol Myers Squibb Co | Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr). |
| KR102730859B1 (ko) | 2017-12-20 | 2024-11-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 및 헤테로아릴 치환된 인돌 화합물 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3728218B1 (en) | 2017-12-20 | 2021-12-01 | Bristol-Myers Squibb Company | Amino indole compounds useful as tlr inhibitors |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| SG11202005733QA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Diazaindole compounds |
| JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
| PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| EP3802539B1 (en) | 2018-06-05 | 2023-09-20 | F. Hoffmann-La Roche AG | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease |
| EP3807270B1 (en) | 2018-06-12 | 2023-09-13 | F. Hoffmann-La Roche AG | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| EP3807271A1 (en) * | 2018-06-13 | 2021-04-21 | F. Hoffmann-La Roche AG | Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease |
| CN112584903B (zh) | 2018-07-23 | 2025-12-23 | 豪夫迈·罗氏有限公司 | 用于自身免疫性疾病治疗的哌嗪化合物 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| EP3847169A1 (en) | 2018-09-04 | 2021-07-14 | F. Hoffmann-La Roche AG | Benzothiazole compounds for the treatment of autoimmune diseases |
| EP3847173B1 (en) | 2018-09-06 | 2023-04-12 | F. Hoffmann-La Roche AG | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| US11548884B2 (en) | 2018-09-06 | 2023-01-10 | Hoffmann-La Roche Inc. | Cyclic amidine compounds for the treatment of autoimmune disease |
| CN112955450A (zh) * | 2018-10-24 | 2021-06-11 | 百时美施贵宝公司 | 经取代的吲哚和吲唑化合物 |
| ES2963696T3 (es) * | 2018-10-24 | 2024-04-01 | Bristol Myers Squibb Co | Compuestos diméricos de indol sustituidos |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| KR102707808B1 (ko) | 2019-03-07 | 2024-09-19 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| CN114072403A (zh) * | 2019-05-07 | 2022-02-18 | 百时美施贵宝公司 | 前药化合物 |
| KR102904576B1 (ko) * | 2019-05-09 | 2025-12-24 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 벤즈이미다졸론 화합물 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| CN110146631B (zh) * | 2019-06-25 | 2021-11-12 | 山西康宝生物制品股份有限公司 | 一种药用材料中聚乙二醇单甲醚残留量的检测方法 |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN119770638A (zh) | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| EP4041730A1 (en) | 2019-10-01 | 2022-08-17 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| CN114829350B (zh) * | 2019-10-04 | 2024-05-28 | 百时美施贵宝公司 | 经取代的咔唑化合物 |
| WO2021084022A1 (en) | 2019-10-31 | 2021-05-06 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| CN114728976B (zh) | 2019-11-19 | 2024-08-16 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物 |
| WO2021099406A1 (en) | 2019-11-20 | 2021-05-27 | F. Hoffmann-La Roche Ag | Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| KR20230023717A (ko) * | 2020-06-11 | 2023-02-17 | 브리스톨-마이어스 스큅 컴퍼니 | 피부 홍반성 루푸스를 치료하기 위한 프레드니솔론 또는 히드록시클로로퀸과 조합된 tlr7 억제제 |
| AU2021296150A1 (en) * | 2020-06-22 | 2023-02-23 | Bristol-Myers Squibb Company | Treating rheumatoid arthritis |
| WO2022022489A1 (zh) * | 2020-07-27 | 2022-02-03 | 江苏恒瑞医药股份有限公司 | 吲哚稠环类衍生物、其制备方法及其在医药上的应用 |
| AU2021328575A1 (en) | 2020-08-19 | 2023-03-16 | Bristol-Myers Squibb Company | Imidazo(1,2-a)pyridine and (1,2,4)triazolo(1,5-a)pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis |
| WO2022040267A1 (en) | 2020-08-19 | 2022-02-24 | Bristol-Myers Squibb Company | 1h-pyrrolo[3,2-c]pyridine and 1h-pyrrolo[2,3-c]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis |
| CN116075510A (zh) | 2020-08-19 | 2023-05-05 | 百时美施贵宝公司 | 1H-苯并[d]咪唑衍生物作为TLR9抑制剂用于治疗纤维化 |
| AU2021385752A1 (en) | 2020-11-26 | 2023-06-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused tricyclic compound, preparation method therefor and application thereof in medicine |
| CN116783202A (zh) * | 2021-02-09 | 2023-09-19 | 吉利德科学公司 | 噻吩并吡咯化合物 |
| CR20230478A (es) | 2021-04-16 | 2023-11-30 | Gilead Sciences Inc | Compuestos de tienopirrol. |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| CN113416188B (zh) * | 2021-05-31 | 2022-12-13 | 河南偶联生物科技有限公司 | 一种[1,2,4]三唑并[1,5-a]吡啶化合物的合成方法 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| KR20240056747A (ko) | 2021-09-10 | 2024-04-30 | 길리애드 사이언시즈, 인코포레이티드 | 티에노피롤 화합물 |
| US20260015324A1 (en) | 2022-07-13 | 2026-01-15 | Bristol-Myers Squibb Company | Processes for Preparing 5-Bromo-3,4-dimethylpyridin-2-amine and 6-Bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine |
| WO2025075944A1 (en) | 2023-10-02 | 2025-04-10 | Bristol-Myers Squibb Company | A method of treating lupus |
| WO2025106385A1 (en) | 2023-11-13 | 2025-05-22 | Bristol-Myers Squibb Company | 2-(4-(2-(7,8-dimethyl-[l,2,4jtriazolo[l,5-a]pyridin-6-yl)-3-isopropyl- lh-indol-5-yl)piperid!n-l-yl)acetamide and crystalline forms thereof |
| TW202527943A (zh) | 2023-11-13 | 2025-07-16 | 美商必治妥美雅史谷比公司 | 2-(4-(2-(7,8-二甲基-[1,2,4]三唑[1,5-a]吡啶-6-基)-3-異丙基-1h-吲哚-5-基)哌啶-1-基)乙醯胺鹽及其結晶形式 |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2026015723A1 (en) * | 2024-07-12 | 2026-01-15 | University Of Maryland, Baltimore | Methods of treating ischemia/reperfusion injury |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000035886A2 (en) | 1998-12-18 | 2000-06-22 | Axys Pharmaceuticals, Inc. | (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors |
| BRPI0411514A (pt) | 2003-06-20 | 2006-08-01 | Coley Pharm Gmbh | antagonistas de receptor toll-like de molécula pequena |
| WO2006113458A1 (en) * | 2005-04-15 | 2006-10-26 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of protein arginine methyl transferases |
| CA2648652A1 (en) | 2006-04-04 | 2007-10-11 | Myriad Genetics, Inc. | Compounds for diseases and disorders |
| DE102006033109A1 (de) | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| JP2010511018A (ja) | 2006-12-01 | 2010-04-08 | ガラパゴス・ナムローゼ・フェンノートシャップ | 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物 |
| WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
| WO2009030996A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Triazole compounds as toll-like receptor (tlr) agonists |
| FR2926556B1 (fr) * | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| WO2010036905A1 (en) | 2008-09-26 | 2010-04-01 | Eisai R & D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| US8785489B2 (en) | 2008-10-17 | 2014-07-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors |
| KR20110132564A (ko) | 2009-02-11 | 2011-12-08 | 선오비온 파마슈티컬스 인코포레이티드 | 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법 |
| MX2011013437A (es) | 2009-06-10 | 2012-02-21 | Sunovion Pharmaceuticals Inc | Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos. |
| TWI462920B (zh) * | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JP5864417B2 (ja) | 2009-07-16 | 2016-02-17 | マリンクロッド エルエルシー | トール様受容体９のアンタゴニストとしての（＋）−モルフィナンおよびその治療的使用 |
| WO2012054862A2 (en) | 2010-10-21 | 2012-04-26 | The Brigham And Women's Hospital, Inc. | Agents, compositions, and methods for treating pruritis and related skin conditions |
| DK2663550T3 (en) | 2011-01-12 | 2017-03-27 | Ventirx Pharmaceuticals Inc | SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS |
| CN103562201B (zh) | 2011-01-12 | 2016-10-19 | 帆德制药股份有限公司 | 作为toll样受体调节剂的取代的苯并氮杂卓 |
| WO2012167053A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| KR102052215B1 (ko) | 2011-06-01 | 2019-12-04 | 야누스 바이오테라퓨틱스, 인크. | 신규한 면역 시스템 조절제 |
| KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| DK2731949T3 (en) * | 2011-07-13 | 2018-06-14 | Tiumbio Co Ltd | 2-PYRIDYL-SUBSTITUTED IMIDAZOLS AS ALK5 AND / OR ALK4 INHIBITORS |
| WO2013052550A2 (en) | 2011-10-04 | 2013-04-11 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
| TWI619704B (zh) | 2012-05-18 | 2018-04-01 | 大日本住友製藥股份有限公司 | 羧酸化合物 |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| JP6223563B2 (ja) | 2013-10-14 | 2017-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 選択的に置換されたキノリン化合物 |
| CN105992766A (zh) | 2013-12-13 | 2016-10-05 | 武田药品工业株式会社 | 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物 |
| EP3398948A3 (en) | 2014-08-22 | 2018-12-05 | Janus Biotherapeutics, Inc. | 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
| US9550778B2 (en) | 2014-10-03 | 2017-01-24 | Vanderbilt University | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 |
| CR20180101A (es) | 2015-08-13 | 2018-04-12 | Merck Sharp & Dohme | Compuestos di-nucleóticos cíclicos como agonistas de sting |
| CA3029032C (en) | 2016-06-29 | 2024-10-29 | Kezar Life Sciences | CRYSTAL SALTS OF AN IMMUNOPROTEASOME PEPTIDE INHIBITOR EPOXYCETONE |
| KR102005457B1 (ko) | 2016-06-29 | 2019-07-30 | 한미약품 주식회사 | 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도 |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| BR112019001270A2 (pt) | 2016-07-30 | 2019-04-30 | Bristol-Myers Squibb Company | compostos indol substituídos com dimetoxifenila como inibidores de tlr7, tlr8 ou tlr9 |
| JP7028861B2 (ja) | 2016-09-09 | 2022-03-02 | ブリストル－マイヤーズ スクイブ カンパニー | ピリジル置換のインドール化合物 |
| KR102688509B1 (ko) | 2017-08-04 | 2024-07-24 | 브리스톨-마이어스 스큅 컴퍼니 | [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물 |
| WO2019028302A1 (en) | 2017-08-04 | 2019-02-07 | Bristol-Myers Squibb Company | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS |
| JP7265554B2 (ja) | 2017-11-14 | 2023-04-26 | ブリストル－マイヤーズ スクイブ カンパニー | 置換インドール化合物 |
| KR102781141B1 (ko) | 2017-12-15 | 2025-03-13 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 인돌 에테르 화합물 |
| EA202091484A1 (ru) | 2017-12-18 | 2021-03-25 | Бристол-Маерс Сквибб Компани | 4-азаиндольные соединения |
| MX2020005462A (es) | 2017-12-19 | 2020-09-07 | Bristol Myers Squibb Co | Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr). |
| JP7304352B2 (ja) | 2017-12-19 | 2023-07-06 | ブリストル－マイヤーズ スクイブ カンパニー | ６－アザインドール化合物 |
| WO2019126081A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Amide substituted indole compounds useful as tlr inhibitors |
| EP3728218B1 (en) | 2017-12-20 | 2021-12-01 | Bristol-Myers Squibb Company | Amino indole compounds useful as tlr inhibitors |
| SG11202005733QA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Diazaindole compounds |
| KR102730859B1 (ko) | 2017-12-20 | 2024-11-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 및 헤테로아릴 치환된 인돌 화합물 |
| ES2963696T3 (es) | 2018-10-24 | 2024-04-01 | Bristol Myers Squibb Co | Compuestos diméricos de indol sustituidos |
| CN112955450A (zh) | 2018-10-24 | 2021-06-11 | 百时美施贵宝公司 | 经取代的吲哚和吲唑化合物 |
-
2017
- 2017-06-27 US US15/635,055 patent/US10071079B2/en not_active Ceased
- 2017-06-28 PT PT177374428T patent/PT3478682T/pt unknown
- 2017-06-28 KR KR1020197002353A patent/KR102473482B1/ko active Active
- 2017-06-28 SM SM20210513T patent/SMT202100513T1/it unknown
- 2017-06-28 ES ES17737442T patent/ES2886964T3/es active Active
- 2017-06-28 SI SI201730890T patent/SI3478682T1/sl unknown
- 2017-06-28 WO PCT/US2017/039633 patent/WO2018005586A1/en not_active Ceased
- 2017-06-28 UY UY0001037310A patent/UY37310A/es active IP Right Grant
- 2017-06-28 PE PE2018003329A patent/PE20190324A1/es unknown
- 2017-06-28 PL PL17737442T patent/PL3478682T3/pl unknown
- 2017-06-28 DK DK17737442.8T patent/DK3478682T3/da active
- 2017-06-28 SG SG11201811590RA patent/SG11201811590RA/en unknown
- 2017-06-28 HR HRP20211261TT patent/HRP20211261T8/hr unknown
- 2017-06-28 CN CN201780052726.1A patent/CN109641895B/zh active Active
- 2017-06-28 EA EA201990048A patent/EA037530B1/ru not_active IP Right Cessation
- 2017-06-28 MY MYPI2018002975A patent/MY196474A/en unknown
- 2017-06-28 RS RS20211090A patent/RS62292B1/sr unknown
- 2017-06-28 AU AU2017287902A patent/AU2017287902B2/en active Active
- 2017-06-28 LT LTEPPCT/US2017/039633T patent/LT3478682T/lt unknown
- 2017-06-28 TW TW106121570A patent/TWI636053B/zh active
- 2017-06-28 EP EP17737442.8A patent/EP3478682B1/en active Active
- 2017-06-28 JP JP2018568837A patent/JP6995067B6/ja active Active
- 2017-06-28 HU HUE17737442A patent/HUE056091T2/hu unknown
- 2017-06-28 MX MX2018015422A patent/MX376212B/es active IP Right Grant
- 2017-06-28 AR ARP170101788A patent/AR108905A1/es active IP Right Grant
-
2018
- 2018-07-23 US US16/042,116 patent/US10478424B2/en not_active Ceased
- 2018-12-25 IL IL263961A patent/IL263961B/en active IP Right Grant
- 2018-12-27 CL CL2018003821A patent/CL2018003821A1/es unknown
-
2019
- 2019-01-24 CO CONC2019/0000686A patent/CO2019000686A2/es unknown
- 2019-01-28 ZA ZA2019/00571A patent/ZA201900571B/en unknown
- 2019-10-15 US US16/653,297 patent/US10912766B2/en not_active Ceased
-
2020
- 2020-12-07 US US17/113,495 patent/US11672780B2/en active Active
-
2021
- 2021-09-15 CY CY20211100814T patent/CY1124514T1/el unknown
-
2022
- 2022-01-25 US US17/584,139 patent/USRE49880E1/en active Active
- 2022-01-25 US US17/584,147 patent/USRE49931E1/en active Active
- 2022-01-25 US US17/584,155 patent/USRE49893E1/en active Active
-
2023
- 2023-04-26 US US18/307,119 patent/US20230255941A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019523241A5 (https=) | ||
| JP7602538B2 (ja) | 二環式化合物及びその使用 | |
| CA2716679C (en) | Amido-thiophene compounds and their use | |
| ES2280768T3 (es) | Inhibidores de histona desacetilasa. | |
| CA2796297C (en) | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanone and related compounds and their use | |
| AU2002334205B8 (en) | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | |
| JP2013525433A5 (https=) | ||
| CA2560689C (en) | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes | |
| KR101504787B1 (ko) | 아졸카복사마이드 화합물 또는 그 염 | |
| JP2020529436A5 (https=) | ||
| JP6186434B2 (ja) | 窒素複素環誘導体及びその医薬品への応用 | |
| AR108905A1 (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo | |
| RU2016115868A (ru) | Замещенные гетероциклические сульфонамидные соединения, полезные в качестве модуляторов trpa 1 | |
| AU2009223693A1 (en) | Azabicyclo [3.2.1] octyl derivatives as 11 beta-HSD1 modulators | |
| JP7438962B2 (ja) | 受容体阻害剤、同阻害剤を含む医薬組成物及びその使用 | |
| BG61295B2 (bg) | Нови естери на тиенилкарбоксилни киселини с аминоалкохоли, техни кватернерни продукти,както и получаване и използване на тези съединения | |
| EA011161B1 (ru) | 3- или 4-монозамещённые производные фенола и тиофенола, полезные в качестве h-лигандов | |
| AU2022202916B2 (en) | Polycyclic amines as opioid receptor modulators | |
| JP2013525448A5 (https=) | ||
| CA2972952A1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
| WO2023125182A1 (zh) | 一种丙酸衍生物及其在医药上的应用 | |
| KR880013897A (ko) | 약리학적 활성을 가진 치환 벤즈아미드 | |
| JP2010527344A5 (https=) | ||
| RU2009145296A (ru) | Бициклосульфониловая кислота (bcsa) и ее применение в качестве терапевтического агента | |
| CA2714352A1 (en) | Dual pharmacophores-pde4-muscarinic antagonistics |